WASHINGTON, D.C. – The latest Securities and Exchange Commission filings show 26 additional publicly traded companies secured over $56 million in SBA Paycheck Protection Program (PPP) funds meant for struggling small businesses on main street,…
Read moreWASHINGTON, D.C. – The latest Securities and Exchange Commission filings show 30 additional publicly traded companies secured over $34 million in SBA Paycheck Protection Program (PPP) funds meant for struggling small businesses on…
Read moreWashington, DC – Today, Patients Over Pharma reacted to comments from the CEO of Sanofi assuring Americans that they will get “first dibs” on its COVID-19 vaccine that is being developed using…
Read moreBloomberg: “Slaoui sits on the boards of several companies involved in the vaccine chase, presenting a potential conflict of interest...As a board member in 2019, Slaoui earned $490,000…
Read moreWashington, DC – Today, Patients Over Pharma released the following statement on the introduction in the House of Representatives of the Heroes Act. “Patients and families across the country are suffering through a public…
Read moreWASHINGTON, D.C. – The latest Securities and Exchange Commission filings show 32 additional publicly traded companies secured over $75 million in SBA Paycheck Protection Program funds meant for struggling small businesses on main…
Read moreAxios: “Trump officials’ dysfunction harms delivery of coronavirus drug” Politico: “Gilead has said it is not involved in deciding…
Read moreWASHINGTON, D.C. – Despite Secretary of the Treasury Mnuchin’s protestations that the Trump SBA’s Paycheck Protection Program has been fixed, Wednesday’s Securities and Exchange Commission filings reveal that at least twelve…
Read moreWatchdog Group Analysis Finds Administration Bailed Out Large Companies with ‘Financial Issues’ Long Before Coronavirus Outbreak *Read the Analysis Here* WASHINGTON, D.C. – In recent days, President Trump, Treasury Secretary Mnuchin,…
Read moreNew analysis: Gilead could price remdesivir at $1 and STILL make a profit Gilead claims $1B in total development costs for remdesivir….less than what they paid out to shareholders in…
Read more**Read the new report HERE** Eli Lilly claim: “using all available resources” to fight coronavirus” → Eli Lilly reality: no increase in annual R&D from projections…additional $250M in revenue. Johnson…
Read moreGilead Q1 2020: $874M in cash dividends, $1.3B in stock buybacks, stock up 20% Gilead CEO cites responsibilities to shareholders, claims it’s “too premature” to speculate on COVID-19 profits REMINDER: Remdesivir discovered…
Read more